Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

28.75 -0.83 (-2.81%)

Streaming Delayed Price Updated: 10:47 AM EDT, Mar 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	665,033
Open	29.23
Bid (Size)	28.73 (100)
Ask (Size)	28.75 (300)
Prev. Close	29.58
Today's Range	28.58 - 29.35
52wk Range	8.730 - 30.33
Shares Outstanding	692,072,184
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗

March 04, 2026

BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more...

Via The Motley Fool

Performance

YTD	+31.2%	+31.2%
1 Month	+3.9%	+3.9%
3 Month	+42.0%	+42.0%
6 Month	+108.8%	+108.8%
1 Year	+172.5%	+172.5%

More News

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗

March 04, 2026

Via Stocktwits

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗

February 06, 2026

Via Stocktwits

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗

March 03, 2026

Via Stocktwits

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

March 03, 2026

From Arbutus Biopharma Corporation

Via GlobeNewswire

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

March 03, 2026

From Roivant Sciences

Via GlobeNewswire

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

March 03, 2026

From Roivant Sciences

Via GlobeNewswire

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗

February 13, 2026

Via The Motley Fool

TTMI Stock Soars 250% in One Year, and One Fund Is Betting $7 Million on More Growth ↗

February 13, 2026

Via The Motley Fool

Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out ↗

February 13, 2026

Via The Motley Fool

The market is filled with gapping stocks in Friday's session. ↗

February 06, 2026

Via Chartmill

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 06, 2026

Via Chartmill

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

February 06, 2026

From Roivant Sciences

Via GlobeNewswire

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

February 06, 2026

From Pulmovant, Inc.

Via GlobeNewswire

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

February 06, 2026

From Roivant Sciences

Via GlobeNewswire

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

Via MarketMinute

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

January 23, 2026

From Roivant Sciences

Via GlobeNewswire

Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗

December 11, 2025

Via Benzinga

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

December 11, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?

Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.

What exchange does Roivant Sciences Ltd. - Common Shares trade on?

Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?

The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market

What is the current price of Roivant Sciences Ltd. - Common Shares?

The current price of Roivant Sciences Ltd. - Common Shares is 28.75

When was Roivant Sciences Ltd. - Common Shares last traded?

The last trade of Roivant Sciences Ltd. - Common Shares was at 03/12/26 10:47 AM ET

What is the market capitalization of Roivant Sciences Ltd. - Common Shares?

The market capitalization of Roivant Sciences Ltd. - Common Shares is 19.90B

How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?

Roivant Sciences Ltd. - Common Shares has 20B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.